Use of octreotide in the treatment of chylopericardium

Eszter Szabados, K. Tóth, E. Mezősi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Chylopericardium involves the pericardial effusion of chyle, which can be a primary (idiopathic) or secondary condition to injury or obstruction of the thoracic duct. We present a case of isolated chylopericardium that appeared after coronary artery bypass grafting in a 46-year-old woman. After failure of the usual conservative therapy for chylopericardium, ie, pericardial drainage and a low-fat, medium-chain triglyceride diet, her treatment was completed with octreotide, a long-acting somatostatin analog. Octreotide was used subcutaneously at a 3 × 100 μg daily dose for 2 weeks. The production of pericardial fluid decreased gradually, and had normalized by the end of treatment. No side effects were evident during therapy.

Original languageEnglish
Pages (from-to)574-575
Number of pages2
JournalHeart and Lung: Journal of Acute and Critical Care
Volume40
Issue number6
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Octreotide
Pericardial Effusion
Chyle
Thoracic Duct
Therapeutics
Somatostatin
Coronary Artery Bypass
Drainage
Triglycerides
Fats
Diet
Wounds and Injuries

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Critical Care and Intensive Care Medicine
  • Pulmonary and Respiratory Medicine

Cite this

Use of octreotide in the treatment of chylopericardium. / Szabados, Eszter; Tóth, K.; Mezősi, E.

In: Heart and Lung: Journal of Acute and Critical Care, Vol. 40, No. 6, 11.2011, p. 574-575.

Research output: Contribution to journalArticle

@article{e4b5dc04be7d4284aaef74b54de2edf1,
title = "Use of octreotide in the treatment of chylopericardium",
abstract = "Chylopericardium involves the pericardial effusion of chyle, which can be a primary (idiopathic) or secondary condition to injury or obstruction of the thoracic duct. We present a case of isolated chylopericardium that appeared after coronary artery bypass grafting in a 46-year-old woman. After failure of the usual conservative therapy for chylopericardium, ie, pericardial drainage and a low-fat, medium-chain triglyceride diet, her treatment was completed with octreotide, a long-acting somatostatin analog. Octreotide was used subcutaneously at a 3 × 100 μg daily dose for 2 weeks. The production of pericardial fluid decreased gradually, and had normalized by the end of treatment. No side effects were evident during therapy.",
author = "Eszter Szabados and K. T{\'o}th and E. Mezősi",
year = "2011",
month = "11",
doi = "10.1016/j.hrtlng.2010.01.004",
language = "English",
volume = "40",
pages = "574--575",
journal = "Heart and Lung: Journal of Acute and Critical Care",
issn = "0147-9563",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Use of octreotide in the treatment of chylopericardium

AU - Szabados, Eszter

AU - Tóth, K.

AU - Mezősi, E.

PY - 2011/11

Y1 - 2011/11

N2 - Chylopericardium involves the pericardial effusion of chyle, which can be a primary (idiopathic) or secondary condition to injury or obstruction of the thoracic duct. We present a case of isolated chylopericardium that appeared after coronary artery bypass grafting in a 46-year-old woman. After failure of the usual conservative therapy for chylopericardium, ie, pericardial drainage and a low-fat, medium-chain triglyceride diet, her treatment was completed with octreotide, a long-acting somatostatin analog. Octreotide was used subcutaneously at a 3 × 100 μg daily dose for 2 weeks. The production of pericardial fluid decreased gradually, and had normalized by the end of treatment. No side effects were evident during therapy.

AB - Chylopericardium involves the pericardial effusion of chyle, which can be a primary (idiopathic) or secondary condition to injury or obstruction of the thoracic duct. We present a case of isolated chylopericardium that appeared after coronary artery bypass grafting in a 46-year-old woman. After failure of the usual conservative therapy for chylopericardium, ie, pericardial drainage and a low-fat, medium-chain triglyceride diet, her treatment was completed with octreotide, a long-acting somatostatin analog. Octreotide was used subcutaneously at a 3 × 100 μg daily dose for 2 weeks. The production of pericardial fluid decreased gradually, and had normalized by the end of treatment. No side effects were evident during therapy.

UR - http://www.scopus.com/inward/record.url?scp=80053983926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053983926&partnerID=8YFLogxK

U2 - 10.1016/j.hrtlng.2010.01.004

DO - 10.1016/j.hrtlng.2010.01.004

M3 - Article

C2 - 20561867

AN - SCOPUS:80053983926

VL - 40

SP - 574

EP - 575

JO - Heart and Lung: Journal of Acute and Critical Care

JF - Heart and Lung: Journal of Acute and Critical Care

SN - 0147-9563

IS - 6

ER -